Thomas J Arneson
Overview
Explore the profile of Thomas J Arneson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi M, Solid C, Chia V, Blaes A, Page J, Barron R, et al.
Support Care Cancer
. 2014 Feb;
22(6):1619-28.
PMID: 24492928
Purpose: Febrile neutropenia (FN) is a common and serious complication of myelosuppressive chemotherapy. Guidelines recommend primary granulocyte colony-stimulating factors (G-CSF) prophylaxis (PPG) in patients with a high risk (HR, >20...
2.
Arneson T, Li S, Liu J, Kilpatrick R, Newsome B, St Peter W
Am J Kidney Dis
. 2013 May;
62(4):747-54.
PMID: 23631997
Background: Changes in mineral and bone disorder treatment patterns and demographic changes in the dialysis population may have influenced hip fracture rates in US dialysis patients in 1993-2010. Study Design:...
3.
Cetin K, Li S, Blaes A, Stryker S, Liede A, Arneson T
Urology
. 2013 Apr;
81(6):1184-9.
PMID: 23601449
Objective: To provide the first comprehensive assessment of the number of men exposed to continuous androgen deprivation therapy (ADT) in the nonmetastatic setting in the United States. Methods: We assembled...
4.
Weinhandl E, Arneson T, St Peter W
Am J Kidney Dis
. 2013 Apr;
62(3):557-67.
PMID: 23597860
Background: Reducing medication-related problems and improving medication adherence in hemodialysis patients may improve clinical outcomes. In 2005, a large US dialysis organization created an integrated pharmacy program for its patients....
5.
Gilbertson D, Peng Y, Arneson T, Dunning S, Collins A
BMC Nephrol
. 2013 Feb;
14:44.
PMID: 23425362
Background: Some hemodialysis patients require large doses of erythropoiesis-stimulating agents (ESAs) to manage anemia. These patients, termed "ESA hyporesponsive," have been characterized using various definitions. We applied three definitions of...
6.
Li S, Peng Y, Weinhandl E, Blaes A, Cetin K, Chia V, et al.
Clin Epidemiol
. 2012 May;
4:87-93.
PMID: 22570568
Background: The prevalence of metastatic bone disease in the US population is not well understood. We sought to estimate the current number of US adults with metastatic bone disease using...
7.
Arneson T, Li S, Gilbertson D, Bridges K, Acquavella J, Collins A
Pharmacoepidemiol Drug Saf
. 2012 Mar;
21(8):857-64.
PMID: 22450901
Purpose: In July 2007, the Centers for Medicare & Medicaid Services released a national coverage determination (NCD) for erythropoiesis-stimulating agent (ESA) use in cancer patients, mandating payment restrictions likely to...
8.
Weinhandl E, Liu J, Gilbertson D, Arneson T, Collins A
J Am Soc Nephrol
. 2012 Feb;
23(5):895-904.
PMID: 22362906
Frequent hemodialysis improves cardiovascular surrogates and quality-of-life indicators, but its effect on survival remains unclear. We used a matched-cohort design to assess relative mortality in daily home hemodialysis and thrice-weekly...
9.
Gilbertson D, Guo H, Arneson T, Collins A
Nephrol Dial Transplant
. 2011 Feb;
26(9):2934-9.
PMID: 21317410
Background: Few studies have examined the effectiveness of pneumococcal vaccination (alone or with influenza vaccination) in improving hemodialysis patient outcomes. We aimed to describe vaccination rates between 2003-2005 and to...
10.
Foley R, Roberts T, Liu J, Gilbertson D, Arneson T, Dunning S, et al.
Am J Nephrol
. 2010 May;
31(6):518-26.
PMID: 20453497
Background/aims: Concern has emerged that erythropoiesis-stimulating agents (ESAs) may decrease survival for cancer patients; many patients beginning dialysis have previous cancer diagnoses. As ESA doses have more than tripled in...